One in nine New Zealand women get breast cancer in their lifetimes, and around 16% of metastatic breast cancers are ...
Researchers at Baylor College of Medicine and Rice University have received a $2.3 million Breakthrough Award from the ...
Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news. If you’re covering the American Society of Hematology (ASH) Annual Meeting, Dec. 7-10 in San ...
The phase 1/2 study will assess next-generation immunotherapy alone and in combination with an immune checkpoint inhibitor in ...
A new study has shed light on a previously poorly understood aspect of breast cancer recurrence: how cancer cells survive in bone marrow despite targeted therapies.
An expert discusses the next steps for patients with metastatic breast cancer after their disease no longer responds to ...
Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...
Barbara O’Brien, MD, discusses the next steps of the phase 2 TBCRC049 study for the treatment of patients with HER2-positive ...
The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ ...
Sarah Sammons, MD, discusses some of the challenges seen with different regimens for HER2-positive metastatic breast cancer ...
SABCS ® "Spotlight” poster to be presented on Wednesday, December 11, 2024 7:00 AM - 8:30 AM CST highlights positive BriaCell survival and clinical benefit data across all metastatic breast cancer ...